Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study

Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study

Abstract Introduction Bimekizumab and brodalumab are characterized by a different mechanism of action if compared to the other anti-interleukin (IL)-17s which target IL-17A. Indeed, brodalumab acts on IL-17RA whereas bimekizumab acts on IL-17A, IL-17F, and IL-17AF cytokines. Currently, despite real-...

Full description

Saved in:
Bibliographic Details
Main Authors: Luca Potestio, Fabrizio Martora, Flavia Raia, Gioacchino Lucagnano, Claudio Brescia, Ginevra Torta, Matteo Megna
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-02-01
Series:Dermatology and Therapy
Subjects:
Bimekizumab
Brodalumab
Comparison
Real-world evidence
Real-life setting
Psoriasis
Online Access:https://doi.org/10.1007/s13555-025-01361-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items